Back to top
more

Vanda Pharmaceuticals (VNDA)

(Real Time Quote from BATS)

$7.20 USD

7.20
100,820

-0.09 (-1.24%)

Updated Apr 9, 2026 11:06 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.93%
2Buy18.12%
3Hold10.10%
4Sell5.65%
5Strong Sell2.94%
S&P50011.36%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Innocoll (INNL) Down on FDA's Refusal to File Xaracoll NDA

by Zacks Equity Research

Innocoll (INNL) announced that it has received a Refusal to File letter from the FDA in connection with the NDA for Xaracoll for the treatment of postsurgical pain.

    Zacks Equity Research

    Abbott to Sell 2 Medical Device Businesses for St. Jude Buyout

    by Zacks Equity Research

    Abbott Laboratories (ABT) has agreed to divest two medical device businesses in order to settle Federal Trade Commission (FTC) charges in relation to its proposed acquisition of St. Jude Medical (STJ).

      Zacks Equity Research

      ImmunoGen: Phase I Data on Ovarian Cancer Drug Published

      by Zacks Equity Research

      ImmunoGen, Inc. (IMGN) announced that data from a 46-patient phase I expansion cohort study on its lead pipeline candidate, mirvetuximab soravtansine (IMGN853), were published in the Journal of Clinical Oncology.

        Zacks Equity Research

        BioMarin (BMRN) Raised to Buy: Should You Add the Stock?

        by Zacks Equity Research

        The Zacks Investment Research upgraded BioMarin (BMRN) to a Zacks #2 Rank (Buy).

          Zacks Equity Research

          Galena Biopharma Reveals Regulatory Pathway for GALE-401

          by Zacks Equity Research

          Galena (GALE) confirmed the regulatory pathway to advance GALE-401 (anagrelide CR) into a pivotal phase III study.

            Zacks Equity Research

            Amphastar Stock Down on CRL for Asthma Drug in the U.S.

            by Zacks Equity Research

            Amphastar Pharmaceuticals, Inc. (AMPH) announced that its subsidiary, Armstrong Pharmaceuticals, Inc., has received a Complete Response Letter (CRL) from the FDA for Primatene Mist (epinephrine inhalation aerosol).

              Zacks Equity Research

              Shire Gets FDA Approval for Label Expansion of Adynovate

              by Zacks Equity Research

              Shire announced that the FDA has approved the use of hemophilia A drug, Adynovate,in pediatric patients under 12 years of age

                Zacks Equity Research

                Seattle Genetics' Acute Myeloid Leukemia Drug on FDA Hold

                by Zacks Equity Research

                Seattle (SGEN) announced that the FDA had placed a clinical hold or partial clinical hold on several early-stage studies on SGN-CD33A for the treatment of AML.

                  Zacks Equity Research

                  Why Vanda Pharmaceuticals (VNDA) Might Be a Diamond in the Rough

                  by Zacks Equity Research

                  Solid estimate revisions and an impressive Zacks Rank suggest that better days may be ahead for Vanda Pharmaceuticals (VNDA) and that now might be an interesting buying opportunity.

                    Zacks Equity Research

                    Aerie (AERI) Rhopressa Regulatory Application Delayed Again

                    by Zacks Equity Research

                    Aerie (AERI)'s NDA for lead candidate, Rhopressa, gets delayed again due to delay on the manufacturer's part.